ISCIII

Inicio de sesión
Selecionar página

Publicaciones

  1. Segura B, Portela M, Hernández San Miguel E, Jarabo-Blázquez P, Argudo I, Sáiz A, Sánchez-Gómez P*, Casas-Tintó S*. (* Co-corresponding authors). (2017) Mechanisms for EGFR signaling regulation by intracellular trafficking in Glioblastoma. Submitted.
  2. Hernández San Miguel E, Núñez-Hervada P, Sanz E, Sánchez-Gómez P. (2017) Ocoxin® oral solution slows down tumor growth and synergizes with temozolomide in experimental models of glioblastoma. Submitted.
  3. Sepúlveda-Sánchez JM, Vaz MA, Balañá C, Gil-Gil M, Reynés G, Gallego O, Martínez-García M, Vicente E, Quindós M, Luque R, Ramos A, Ruano Y, Pérez-Segura P, Benavides M, Sánchez-Gómez P, Hernández-Laín A. (2017) Phase II trial of dacomitinib, a pan-HER (human epidermal growth factor receptor) tyrosine kinase inhibitor, in recurrent GB patients with EGFR amplification. Neuro Oncol. On line in June 201

    doi: 10.1093/neuonc/nox105

  4. Ayuso JM, Monge R, Martínez-González A, Virumbrales-Muñoz M, Llamazares GA, Berganzo J, Hernández-Laín, A, Santolaria J, Doblaré M, Hubert C, Rich JN, Sánchez-Gómez P, Pérez-García VM, Ochoa I, Fernández LJ. (2017) Glioblastoma on a microfluidic chip: Generating pseudopalisades and enhancing aggressiveness through blood vessel obstruction events. Neuro Oncol. 19(4):503-513. PMID: 28062831

    doi: 10.1093/neuonc/now230

  5. Talamillo A, Grande L, Ruiz-Ontañón P, Velasquez C, Mollinedo P, Torices S, Sanchez-Gomez P, Aznar A, Esparis-Ogando A, Lopez-Lopez C, Lafita C, Berciano MT, Montero JA, Vázquez Barquero A, Segura V, Villagra NT, Pandiella A, Lafarga M, Leon J, Martínez-Climent JA, Sanz-Moreno V, Fernandez-Luna JL. (2017) ODZ1 allows glioblastoma to sustain invasiveness through a Myc-dependent transcriptional upregulation of RhoA. Oncogene 6(12): 1733-1744. PMID: 27641332

    doi: 10.1038/onc.2016.341

  6. Villanueva AA, Falcón P, Espinoza N, R LS, Milla LA, Hernández-SanMiguel E, Torres VA, Sanchez-Gomez P, Palma V. (2017) The Netrin-4/ Neogenin-1 axis promotes neuroblastoma cell survival and migration. Oncotarget 8(6):9767-9782. PMID: 28038459

    doi: 18632/oncotarget.14213

  7. Pérez-García VM, Fitzpatrick S, Pérez-Romasanta LA, Pesic M, Schucht P, Arana E, Sánchez-Gómez P. (2016) Applied mathematics and nonlinear sciences in the war on cancer. App. Math. Nonlin. Sci. 1(2): 423–436

    doi: 10.21042/AMNS.2016.2.00036

  8. García-Romero N, González-Tejedo C, Carrión-Navarro J, Esteban-Rubio S, Rackov G, Rodríguez-Fanjul V, Oliver-De La Cruz J, Prat-Acín R, Peris-Celda M, Blesa D, Ramírez-Jiménez L, Sánchez-Gómez P, Perona R, Escobedo-Lucea C, Belda-Iniesta C, Ayuso-Sacido A. (2016) Cancer stem cells from human glioblastoma resemble but do not mimic original tumors after in vitro passaging in serum-free media. Oncotarget 7(40):65888-65901. PMID: 27589567

    doi: 10.18632/oncotarget.1167

  9. Zahonero C, Aguilera P, Ramírez-Castillejo C, Pajares M, Bolós MV, Cantero C, Pérez-Núñez A,  Hernández-Laín A, Sánchez-Gómez P*, Sepúlveda JM*. (* Co-corresponding authors) (2015) Preclinical test of dacomitinib, an irreversible EGFR inhibitor, confirms its effectiveness for glioblastoma. Mol. Can. Ther. 14(7):1548-58. PMID: 25939761

    doi: 10.1158/1535-7163.MCT-14-0736

  10. Zahonero C, Sepúlveda JM, Sánchez-Gómez P. (2015) Epidermic growth factor receptor (EGFR) in glioblastomas: the mechanism of tumorigenesis and its role as a therapeutic target. Rev. Neurol. 61(2):85-93. PMID: 26156444

    https://www.neurologia.com/articulo/2014535

  11. Fernández-Martínez P; Zahonero C; Sánchez-Gómez P. (2015) DYRK1A: the double-edged kinase as a protagonist in cell growth and tumorigenesis. Mol.Cel.Onc. 2 (1). PMID: 27308401

    doi: 10.4161/23723548.2014.970048

  12. González-Gómez P, Crecente-Campo J, Zahonero C, de la Fuente M, Hernández-Laín A, Mira H*, Sánchez-Gómez P*, García-Fuentes M* (* Co-corresponding authors). (2015) Controlled release microspheres loaded with BMP7 suppress primary tumors from human glioblastoma. Oncotarget, 6 (13): 10950-10963. PMID: 25860932

    doi: 10.18632/oncotarget.3459

  13. Zahonero C and Sánchez-Gómez P. (2014) EGFR-dependent mechanisms in glioblastoma: towards a better therapeutic strategy. Cel. Mol. Life Sci. 71 (18): 3465-88. PMID: 24671641

    doi: 10.1007/s00018-014-1608-1

  14. Leon G, Sánchez-Ruiloba L, Pérez-Rodríguez A, Gragera T, Martinez N, Hernández S, Anta B, Calero O, Garcia-Dominguez CA, Dura LM, Peña-Jiménez D, Castro J, Zarich N, Sanchez-Gomez P, Calero M, Iglesias T, Oliva JL, Rojas JM. (2014) Shoc2/Sur8 protein regulates neurite outgrowth. PLoS One 16; 9(12):e114837. PMID: 25514808

    doi: 10.1371/journal.pone.0114837

  15. Pozo Zahonero, Fernández P, Liñares JM, Ayuso A, Hagiwara M, Pérez A, Ricoy JR, Hernández-Laín A, Sepúlveda JM, Sánchez-Gómez P. (2013) Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth. J. Clin. Invest. 123(6):2475-87. PMID: 23635774

    doi: 10.1172/JCI63623